News Releases

Home / Investor Relations

 

News Releases

Date Title and Summary
Toggle Summary Tyme Appoints Accomplished Healthcare Executive Douglas A. Michels to Board of Directors
Former OraSure Technologies President and CEO and Johnson and Johnson executive to join Tyme board of directors James Biehl appointed as Chief Legal Officer of Tyme ; to step down from the board of directors NEW YORK , Sept. 18, 2018 (GLOBE NEWSWIRE) --   Tyme Technologies, Inc.
Toggle Summary Tyme Exceeds Enrollment Expectations for the Phase II Trial of SM-88 in Pancreatic Cancer
NEW YORK , Sept. 05, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), today announced that the number of currently consented or randomized subjects has exceeded the enrollment target for the Stage 1 dose selection portion of the Company’s Phase II trial in metastatic pancreatic
Toggle Summary Tyme Technologies, Inc. to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
NEW YORK , Aug. 27, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced that it will be featured as a presenting company at the Rodman & Renshaw 20th Annual Global Investment Conference
Toggle Summary Tyme Technologies Provides Clinical and Corporate Update for Fiscal 1Q 2019
NEW YORK , July 30, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced a clinical and corporate update for the fiscal quarter ended June 30, 2018 .
Toggle Summary Tyme Technologies, Inc. Set to Join Russell 3000® Index
NEW YORK , June 25, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced it is set to join the Russell 3000 ®  Index at the conclusion of the Russell U.S.
Toggle Summary Tyme Releases Detailed Data and Analyses with SM-88 From the First Human Study and Compassionate Use Programs
NEW YORK , June 12, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today release detailed patient data and analyses from both the First Human Study (FHS) and Compassionate Use Program of SM-88 in metastatic
Toggle Summary Tyme Appoints Pharma Executive Don DeGolyer to Board of Directors
NEW YORK , May 30, 2018 (GLOBE NEWSWIRE) -- Tyme, Inc. (NASDAQ:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced the appointment of Don DeGolyer to the Company’s board of directors . Mr. DeGolyer is the founder, Chief Executive Officer, and a director of
Toggle Summary Tyme Announces Five Clinical Abstracts at the 2018 ASCO Annual Meeting
NEW YORK , May 17, 2018 (GLOBE NEWSWIRE) -- Tyme , Inc.  (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced the availability of additional clinical data from the Company’s lead candidate SM-88 being presented in five abstracts at the
Toggle Summary Tyme Provides Clinical and Corporate Update for Fiscal Year End 2018
NEW YORK , April 09, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced a clinical and corporate update for the fiscal year ended March 31, 2018 .
Toggle Summary Tyme and JAF Announce Sarcoma Treatment Collaboration
NEW YORK , April 06, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company, today announced that it is collaborating with The Joseph Ahmed Foundation (“JAF”) to provide treatment for metastatic sarcomas. The collaboration will focus on children and young